Gene Dev:鳞状细胞癌患者中DNp63a的作用

2012-09-28 生物谷 生物谷

在美国,每年约70万人被诊断为鳞状细胞癌(SCC)。SCCDNp63a蛋白质是一种常见的致癌因子,其表达在患者体内明显增高,鳞状细胞癌患者身体杀死癌细胞的能力异常低。 近日,科学家认为DNp63a的功能很简单,就如负责识别和杀死癌细胞的肿瘤抑制基因p53那样。在SCC患者中,DNp63a通常是失活的,早期研究提示高表达的DNp63a抑制了p53基因,引发SCC。 科罗拉多大学癌症中心研究人员发

在美国,每年约70万人被诊断为鳞状细胞癌(SCC)。SCCDNp63a蛋白质是一种常见的致癌因子,其表达在患者体内明显增高,鳞状细胞癌患者身体杀死癌细胞的能力异常低。

近日,科学家认为DNp63a的功能很简单,就如负责识别和杀死癌细胞的肿瘤抑制基因p53那样。在SCC患者中,DNp63a通常是失活的,早期研究提示高表达的DNp63a抑制了p53基因,引发SCC。

科罗拉多大学癌症中心研究人员发表在杂志Genes&Development上的研究揭示了DNp63a的作用。在SCC患者中,虽然高表达DNp63a和p53活性低时伴随发生的,但这两者之间没有因果关系,即DNp63a不影响p53的表达。

这项研究主要领导者CU博尔德分校分子、细胞和发育生物学系副教授Joaquin M. Espinosa博士说:DNp63a不通过p53 发挥作用,而是通过抗增殖基因的表观遗传沉默发挥作用。

在下DNp63a存在的情况,DNp63a利用一种称为H2A.Z的蛋白质在体内有效地抑制抗增殖的基因,使抗增殖基因无法发挥防癌抗癌的职责。

DNp63a独立于p53基因,是一种关闭基因,能阻止细胞分裂、关闭抗增殖基因,使得细胞不断分裂增殖。现在已知了DNp63a的功能,Espinosa正在寻找一个治疗药物,Espinosa和他的同事现在在动物模型中探索打破DNp63a机制可能产生的影响。

 

doi:10.1101/gad.198069.112
PMC:
PMID:

ΔNp63α represses anti-proliferative genes via H2A.Z deposition.

1.Corrie L. Gallant-Behm, Matthew R. Ramsey, Claire L. Bensard, Ignacio Nojek, Jack Tran, Minghua Liu, Leif W. Ellisen, and Joaquín M. Espinosa

Transcriptional coregulators control the activity of many transcription factors and are thought to have wide-ranging effects on gene expression patterns. We show here that muscle-specific loss of nuclear receptor corepressor 1 (NCoR1) in mice leads to enhanced exercise endurance due to an increase of both muscle mass and of mitochondrial number and activity. The activation of selected transcription factors that control muscle function, such as MEF2, PPARβ/, and ERRs, underpins these phenotypic alterations. NCoR1 levels are decreased in conditions that require fat oxidation, resetting transcriptional programs to boost oxidative metabolism. Knockdown of gei-8, the sole C. elegans NCoR homolog, also robustly increased muscle mitochondria and respiration, suggesting conservation of NCoR1 function. Collectively, our data suggest that NCoR1 plays an adaptive role in muscle physiology and that interference with NCoR1 action could be used to improve muscle function.

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (4)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1784665, encodeId=4b8a1e846652e, content=<a href='/topic/show?id=fd2d6164d2' target=_blank style='color:#2F92EE;'>#DNp63a#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=6164, encryptionId=fd2d6164d2, topicName=DNp63a)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=236b481, createdName=anan, createdTime=Sun Aug 25 19:10:00 CST 2013, time=2013-08-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1978335, encodeId=a72719e833512, content=<a href='/topic/show?id=3b90e79787f' target=_blank style='color:#2F92EE;'>#细胞癌#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=77978, encryptionId=3b90e79787f, topicName=细胞癌)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e457184, createdName=qingting, createdTime=Tue Oct 23 19:10:00 CST 2012, time=2012-10-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1982193, encodeId=5602198219359, content=<a href='/topic/show?id=13b658e849' target=_blank style='color:#2F92EE;'>#Dev#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5878, encryptionId=13b658e849, topicName=Dev)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=bcaa382, createdName=fzwish20000, createdTime=Tue Dec 04 19:10:00 CST 2012, time=2012-12-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2048481, encodeId=8d42204848147, content=<a href='/topic/show?id=4363e929ad' target=_blank style='color:#2F92EE;'>#Gene#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=7929, encryptionId=4363e929ad, topicName=Gene)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=63a4277, createdName=cy0324, createdTime=Tue Nov 27 22:10:00 CST 2012, time=2012-11-27, status=1, ipAttribution=)]
    2013-08-25 anan
  2. [GetPortalCommentsPageByObjectIdResponse(id=1784665, encodeId=4b8a1e846652e, content=<a href='/topic/show?id=fd2d6164d2' target=_blank style='color:#2F92EE;'>#DNp63a#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=6164, encryptionId=fd2d6164d2, topicName=DNp63a)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=236b481, createdName=anan, createdTime=Sun Aug 25 19:10:00 CST 2013, time=2013-08-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1978335, encodeId=a72719e833512, content=<a href='/topic/show?id=3b90e79787f' target=_blank style='color:#2F92EE;'>#细胞癌#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=77978, encryptionId=3b90e79787f, topicName=细胞癌)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e457184, createdName=qingting, createdTime=Tue Oct 23 19:10:00 CST 2012, time=2012-10-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1982193, encodeId=5602198219359, content=<a href='/topic/show?id=13b658e849' target=_blank style='color:#2F92EE;'>#Dev#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5878, encryptionId=13b658e849, topicName=Dev)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=bcaa382, createdName=fzwish20000, createdTime=Tue Dec 04 19:10:00 CST 2012, time=2012-12-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2048481, encodeId=8d42204848147, content=<a href='/topic/show?id=4363e929ad' target=_blank style='color:#2F92EE;'>#Gene#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=7929, encryptionId=4363e929ad, topicName=Gene)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=63a4277, createdName=cy0324, createdTime=Tue Nov 27 22:10:00 CST 2012, time=2012-11-27, status=1, ipAttribution=)]
  3. [GetPortalCommentsPageByObjectIdResponse(id=1784665, encodeId=4b8a1e846652e, content=<a href='/topic/show?id=fd2d6164d2' target=_blank style='color:#2F92EE;'>#DNp63a#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=6164, encryptionId=fd2d6164d2, topicName=DNp63a)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=236b481, createdName=anan, createdTime=Sun Aug 25 19:10:00 CST 2013, time=2013-08-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1978335, encodeId=a72719e833512, content=<a href='/topic/show?id=3b90e79787f' target=_blank style='color:#2F92EE;'>#细胞癌#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=77978, encryptionId=3b90e79787f, topicName=细胞癌)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e457184, createdName=qingting, createdTime=Tue Oct 23 19:10:00 CST 2012, time=2012-10-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1982193, encodeId=5602198219359, content=<a href='/topic/show?id=13b658e849' target=_blank style='color:#2F92EE;'>#Dev#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5878, encryptionId=13b658e849, topicName=Dev)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=bcaa382, createdName=fzwish20000, createdTime=Tue Dec 04 19:10:00 CST 2012, time=2012-12-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2048481, encodeId=8d42204848147, content=<a href='/topic/show?id=4363e929ad' target=_blank style='color:#2F92EE;'>#Gene#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=7929, encryptionId=4363e929ad, topicName=Gene)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=63a4277, createdName=cy0324, createdTime=Tue Nov 27 22:10:00 CST 2012, time=2012-11-27, status=1, ipAttribution=)]
    2012-12-04 fzwish20000
  4. [GetPortalCommentsPageByObjectIdResponse(id=1784665, encodeId=4b8a1e846652e, content=<a href='/topic/show?id=fd2d6164d2' target=_blank style='color:#2F92EE;'>#DNp63a#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=6164, encryptionId=fd2d6164d2, topicName=DNp63a)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=236b481, createdName=anan, createdTime=Sun Aug 25 19:10:00 CST 2013, time=2013-08-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1978335, encodeId=a72719e833512, content=<a href='/topic/show?id=3b90e79787f' target=_blank style='color:#2F92EE;'>#细胞癌#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=77978, encryptionId=3b90e79787f, topicName=细胞癌)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e457184, createdName=qingting, createdTime=Tue Oct 23 19:10:00 CST 2012, time=2012-10-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1982193, encodeId=5602198219359, content=<a href='/topic/show?id=13b658e849' target=_blank style='color:#2F92EE;'>#Dev#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5878, encryptionId=13b658e849, topicName=Dev)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=bcaa382, createdName=fzwish20000, createdTime=Tue Dec 04 19:10:00 CST 2012, time=2012-12-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2048481, encodeId=8d42204848147, content=<a href='/topic/show?id=4363e929ad' target=_blank style='color:#2F92EE;'>#Gene#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=7929, encryptionId=4363e929ad, topicName=Gene)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=63a4277, createdName=cy0324, createdTime=Tue Nov 27 22:10:00 CST 2012, time=2012-11-27, status=1, ipAttribution=)]
    2012-11-27 cy0324

相关资讯

头颈部皮肤癌切缘阳性患者或可选择临床观察

 据美国耳鼻喉医师协会联合会议上报告的一项回顾性研究结果,头颈部皮肤癌切缘阳性患者除选择再切除术之外,观察或“观察等待”也是一种可接受的选择。 为比较头颈部皮肤癌切缘阳性患者观察等待与再切除的预后情况,西弗吉尼亚州摩根顿克拉克斯堡美国退伍军人医院的Justin Douglas博士及其同事对492例患者进行回顾性研究。患者均在5年前接受头颈部皮肤癌切除术,包括387例基底细胞癌(B

Mol Can Res:鳞状细胞癌侵袭转移新标志物α-catulin

上皮癌特指来源于外胚层和内胚层,发生于上皮细胞的恶性肿瘤。鳞状细胞癌(SCC)是人上皮癌最常见的类型之一。其中头部和颈部鳞状细胞癌(HNSCC),由于后期诊断死亡率居高不下,淋巴结转移的预后差,是一种最具侵略性的癌症类型。 所有癌症过程的发生,都涉及到局部侵袭和远端器官转移,而这两者与临床上肿瘤患者的生存最相关,但至于肿瘤侵袭转移的分子机制一直得不到良好的解释。 在Molecular Canc